ES2150566T3 - Tratamiento de la diabetes. - Google Patents
Tratamiento de la diabetes.Info
- Publication number
- ES2150566T3 ES2150566T3 ES95917874T ES95917874T ES2150566T3 ES 2150566 T3 ES2150566 T3 ES 2150566T3 ES 95917874 T ES95917874 T ES 95917874T ES 95917874 T ES95917874 T ES 95917874T ES 2150566 T3 ES2150566 T3 ES 2150566T3
- Authority
- ES
- Spain
- Prior art keywords
- peptide
- diabetes treatment
- glucagon
- insulin
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
SE FACILITA UN METODO PARA TRATAR LA DIABETES DEPENDIENTE DE INSULINA MEDIANTE UN REGIMEN QUE INCLUYE LA ADMINISTRACION DE INSULINA Y PEPTIDOS INSULINOTROPICOS COMO EL GLUCAGON O PEPTIDOS SIMILARES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9409496A GB9409496D0 (en) | 1994-05-12 | 1994-05-12 | Method for improving glycaemic control in diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2150566T3 true ES2150566T3 (es) | 2000-12-01 |
Family
ID=10755008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95917874T Expired - Lifetime ES2150566T3 (es) | 1994-05-12 | 1995-05-12 | Tratamiento de la diabetes. |
Country Status (13)
Country | Link |
---|---|
US (3) | US6899883B2 (es) |
EP (1) | EP0762890B1 (es) |
JP (2) | JPH10500114A (es) |
AT (1) | ATE194918T1 (es) |
AU (1) | AU711611B2 (es) |
CA (1) | CA2190112A1 (es) |
DE (1) | DE69518154T2 (es) |
DK (1) | DK0762890T3 (es) |
ES (1) | ES2150566T3 (es) |
GB (1) | GB9409496D0 (es) |
GR (1) | GR3034631T3 (es) |
PT (1) | PT762890E (es) |
WO (1) | WO1995031214A1 (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
MA24129A1 (fr) * | 1996-08-30 | 1997-10-01 | Novozymes As | Procede pour deformer une matiere textile cellulosique |
US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
CA2468374C (en) * | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Glp-1 derivatives |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
JP2001516765A (ja) * | 1997-09-12 | 2001-10-02 | ヴォルフ ゲオルグ フォースマン | 真性糖尿病及び肥満の治療のための組成物 |
EP1056774A1 (en) * | 1998-02-27 | 2000-12-06 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
EP1060191B1 (en) * | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
WO1999043707A1 (en) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
US20040037818A1 (en) * | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
EP1105460B1 (en) * | 1998-08-10 | 2009-10-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof |
AU5195699A (en) * | 1998-08-11 | 2000-03-06 | Sumitomo Pharmaceuticals Company, Limited | Blood sugar level controlling agent |
EP1600162A1 (en) * | 1998-12-22 | 2005-11-30 | Eli Lilly & Company | Shelf-stable formulation of glucagon-like peptide-1 |
WO2000037098A1 (en) * | 1998-12-22 | 2000-06-29 | Eli Lilly And Company | Shelf-stable formulation of glucagon-like peptide-1 |
DE60036367T2 (de) | 1999-06-21 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes |
DE60142351D1 (de) | 2000-10-20 | 2010-07-22 | Amylin Pharmaceuticals Inc | Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid |
JP2004520345A (ja) * | 2001-01-12 | 2004-07-08 | ワラター・ファーマシューティカルズ・インク | 糖尿病を有する被験者にガストリン/cck受容体リガンド及びegf受容体リガンド組成物を用いた島細胞新生治療方法の効果持続 |
AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
CA2452044A1 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
JP2005508360A (ja) | 2001-10-19 | 2005-03-31 | イーライ・リリー・アンド・カンパニー | Glp−1およびインスリンの二相混合物 |
US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
CA2476589C (en) * | 2002-02-27 | 2014-02-25 | Pharmain, Ltd. | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
EP1509087A4 (en) * | 2002-05-24 | 2005-12-21 | Waratah Pharmaceuticals Inc | TREATMENT FOR DIABETES |
EP1837031B1 (en) | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
US7560425B2 (en) | 2002-06-07 | 2009-07-14 | Waratah Pharmaceuticals Inc. | Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes |
EP1515749B1 (en) | 2002-06-14 | 2012-08-15 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a glp-1 compound |
JP2006506386A (ja) * | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ, インコーポレイテッド | 糖尿病の処置 |
US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
NZ541365A (en) * | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7655618B2 (en) * | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US20080039379A1 (en) * | 2003-05-27 | 2008-02-14 | Waratah Pharmaceuticals, Inc. | Compositions Comprising Gastrin Compounds and Their Use in Diabetes |
WO2005023291A2 (en) * | 2003-09-11 | 2005-03-17 | Novo Nordisk A/S | Use of glp1-agonists in the treatment of patients with type i diabetes |
CA2554458A1 (en) * | 2004-01-30 | 2005-08-11 | Waratah Pharmaceuticals, Inc. | The combined use of glp-1 agonists and gastrin for regulating blood glucose levels |
EP1765873A4 (en) * | 2004-07-01 | 2009-07-01 | Waratah Pharmaceuticals Inc | COMBINED USE OF CD3 AGONIST AND GASTRIN FOR THE TREATMENT OF DIABETES |
US20090215069A1 (en) * | 2004-07-28 | 2009-08-27 | Andreas Christ | Pancreatic polypeptide as target/marker of beta cell failure |
EP1791554A2 (en) * | 2004-09-17 | 2007-06-06 | Novo Nordisk A/S | Pharmaceutical compositions containing insulin and insulinotropic peptide |
EP1814581B1 (en) * | 2004-11-12 | 2016-03-16 | Novo Nordisk A/S | Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline |
EP1827381A1 (en) * | 2004-12-03 | 2007-09-05 | Mederio AG | A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation |
SE0402976L (sv) * | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
WO2006126688A1 (ja) * | 2005-05-27 | 2006-11-30 | Asubio Pharma Co., Ltd. | インスリン抵抗性改善剤 |
US8658174B2 (en) * | 2005-07-27 | 2014-02-25 | Qinghua Wang | GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes |
JP2009510134A (ja) * | 2005-10-07 | 2009-03-12 | ワラタ ファーマシューティカルズ, インコーポレイテッド | Dpp−iv阻害剤およびガストリン化合物の組み合わせ使用 |
AU2006330610B2 (en) | 2005-12-19 | 2012-08-16 | Pharmain Corporation | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
JP5241849B2 (ja) | 2007-11-16 | 2013-07-17 | ノボ・ノルデイスク・エー/エス | インスリン及びインスリン分泌性ペプチドを含む薬学的組成物 |
US20090176892A1 (en) * | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
EP2504019A2 (en) | 2009-11-25 | 2012-10-03 | ArisGen SA | Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion |
EP2820150A1 (en) * | 2012-03-01 | 2015-01-07 | Novo Nordisk A/S | N-terminally modified oligopeptides and uses thereof |
CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
KR102568272B1 (ko) | 2015-02-11 | 2023-08-21 | 지맥스 바이오팜 엘엘씨 | Glp-1r 항체 융합 단백질의 안정한 약제학적 용액 제형 |
WO2018055539A1 (en) | 2016-09-22 | 2018-03-29 | Wockhardt Limited | Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue |
PE20211202A1 (es) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
EP4090351A4 (en) * | 2020-01-16 | 2023-09-13 | Shanghai Benemae Pharmaceutical Corporation | GLP-1 DOSAGE REGIME |
WO2021142733A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs |
WO2021144476A1 (en) | 2020-02-18 | 2021-07-22 | Novo Nordisk A/S | Pharmaceutical formulations |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK283180A (da) | 1980-07-01 | 1982-01-02 | Novo Industri As | Polypeptider og derivater deraf |
NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
DE68929217T2 (de) | 1989-03-20 | 2000-11-30 | Gen Hospital Corp | Insulinotropes hormon |
EP0512042B1 (en) * | 1990-01-24 | 1998-04-08 | BUCKLEY, Douglas I. | Glp-1 analogs useful for diabetes treatment |
US5187154A (en) * | 1990-12-13 | 1993-02-16 | Board Of Regents, The University Of Texas System | Diagnosis and treatment of humans with diabetes or at risk to develop diabetes |
US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
KR0154880B1 (ko) | 1992-06-15 | 1998-10-15 | 피터 알.셰어러 | 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체 |
US5885956A (en) * | 1992-12-14 | 1999-03-23 | Research Triangle Pharmaceuticals | Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand |
US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
NZ250844A (en) | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5981488A (en) | 1997-03-31 | 1999-11-09 | Eli Lillly And Company | Glucagon-like peptide-1 analogs |
US20040037818A1 (en) * | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
JP2004520345A (ja) * | 2001-01-12 | 2004-07-08 | ワラター・ファーマシューティカルズ・インク | 糖尿病を有する被験者にガストリン/cck受容体リガンド及びegf受容体リガンド組成物を用いた島細胞新生治療方法の効果持続 |
US7202080B2 (en) * | 2001-03-29 | 2007-04-10 | Ixion Biotechnology, Inc. | Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway |
US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
EP1509087A4 (en) * | 2002-05-24 | 2005-12-21 | Waratah Pharmaceuticals Inc | TREATMENT FOR DIABETES |
US7560425B2 (en) * | 2002-06-07 | 2009-07-14 | Waratah Pharmaceuticals Inc. | Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes |
EP1837031B1 (en) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
JP2006506386A (ja) * | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ, インコーポレイテッド | 糖尿病の処置 |
-
1994
- 1994-05-12 GB GB9409496A patent/GB9409496D0/en active Pending
-
1995
- 1995-05-12 US US08/737,446 patent/US6899883B2/en not_active Expired - Fee Related
- 1995-05-12 CA CA002190112A patent/CA2190112A1/en not_active Withdrawn
- 1995-05-12 DK DK95917874T patent/DK0762890T3/da active
- 1995-05-12 AT AT95917874T patent/ATE194918T1/de not_active IP Right Cessation
- 1995-05-12 ES ES95917874T patent/ES2150566T3/es not_active Expired - Lifetime
- 1995-05-12 AU AU24044/95A patent/AU711611B2/en not_active Withdrawn - After Issue
- 1995-05-12 DE DE69518154T patent/DE69518154T2/de not_active Expired - Fee Related
- 1995-05-12 PT PT95917874T patent/PT762890E/pt unknown
- 1995-05-12 JP JP7529262A patent/JPH10500114A/ja not_active Withdrawn
- 1995-05-12 WO PCT/CA1995/000287 patent/WO1995031214A1/en not_active Application Discontinuation
- 1995-05-12 EP EP95917874A patent/EP0762890B1/en not_active Revoked
-
1999
- 1999-03-29 US US09/280,020 patent/US6989148B2/en not_active Expired - Fee Related
-
2000
- 2000-10-16 GR GR20000402317T patent/GR3034631T3/el not_active IP Right Cessation
-
2007
- 2007-02-08 JP JP2007029369A patent/JP2007131640A/ja active Pending
- 2007-12-04 US US11/987,771 patent/US20080286301A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1995031214A1 (en) | 1995-11-23 |
US6989148B2 (en) | 2006-01-24 |
US20020160008A1 (en) | 2002-10-31 |
US6899883B2 (en) | 2005-05-31 |
DK0762890T3 (da) | 2000-11-13 |
JP2007131640A (ja) | 2007-05-31 |
ATE194918T1 (de) | 2000-08-15 |
US20080286301A1 (en) | 2008-11-20 |
AU711611B2 (en) | 1999-10-14 |
DE69518154T2 (de) | 2000-12-14 |
EP0762890B1 (en) | 2000-07-26 |
GB9409496D0 (en) | 1994-06-29 |
DE69518154D1 (de) | 2000-08-31 |
PT762890E (pt) | 2000-11-30 |
AU2404495A (en) | 1995-12-05 |
JPH10500114A (ja) | 1998-01-06 |
CA2190112A1 (en) | 1995-05-12 |
EP0762890A1 (en) | 1997-03-19 |
US20020119146A1 (en) | 2002-08-29 |
GR3034631T3 (en) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2150566T3 (es) | Tratamiento de la diabetes. | |
ATE187647T1 (de) | Verwendung eines peptids | |
ATE193541T1 (de) | Insulinotropes hormon | |
ATE251642T1 (de) | Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides | |
EA200000652A1 (ru) | Кристаллы глюкагоноподобного пептида 1 | |
DE69534678D1 (de) | Glucagonähnliche Peptide, Zusammensetzungen und Verfahren | |
NO940436L (no) | Forlenget avgivelse av peptider | |
NO972169L (no) | Acylerte insulinanaloger | |
ATE252912T1 (de) | Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung | |
PE47096A1 (es) | Analogo, composicion y uso del peptido insulinotropico similar al glucagon | |
DE3889536D1 (de) | Behandlung von krebs mit somatostatin und mit analogen davon. | |
ATE100714T1 (de) | Arzneimittel (calcitoningen verwandte peptide) zur behandlung erektiler dysfunktionen. | |
FI971420A (fi) | Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä | |
MX9704738A (es) | Analogos de peptido p277 y composiciones farmaceuticas que los contienen, metodo de diagnostico de diabetes mellitus dependiente de la insulina y uso de los mismos. | |
DE69429365D1 (de) | Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden | |
EA200000139A1 (ru) | Лечение диабета тиазолидиндионом, средством, стимулирующим секрецию инсулина, и дигуанидом | |
EP1132402A4 (en) | PEPTIDE FRAGMENTS WITH CELL DEATH PREVENTIVE ACTIVITY | |
FI942392A0 (fi) | Peptidejä ja vasta-aineita nivelreuman hoitoon | |
EA200300222A1 (ru) | Лечение гепатита c с помощью тимозина, интерферона и рибавирина | |
Lein | Human growth hormone-great promise at a price |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 762890 Country of ref document: ES |